{"id":"W4286296265","doi":"10.1200/jco.2022.40.16_suppl.5000","title":"TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Hazard ratio; Progression-free survival; Cancer; Overall survival; Urology; Nuclear medicine; Clinical trial; Confidence interval; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003702268,0.0002931993,0.001812222,0.0003914677,0.00008468828,0.00003423547,0.000292451,0.000199327,0.001308186],"category_scores_gemma":[0.000789854,0.0002195827,0.0006182892,0.0004400877,0.0004566918,0.0002648004,0.0001568077,0.001690498,0.000007141826],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008273744,"about_ca_system_score_gemma":0.005003465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003398079,"about_ca_topic_score_gemma":0.001355773,"domain_scores_codex":[0.9938333,0.001188928,0.002575977,0.0004125752,0.001342043,0.0006471463],"domain_scores_gemma":[0.9959214,0.001374045,0.001376208,0.0003154681,0.0005383507,0.0004745752],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.3818743,0.006283747,0.3479719,0.0004746484,0.004440354,0.02414139,0.009528857,0.0009186601,0.001025967,0.00005443012,0.002214426,0.2210714],"study_design_scores_gemma":[0.1493449,0.03950299,0.7473028,0.000858326,0.002205986,0.000305984,0.006541357,0.0007517505,0.0003253368,0.0008499588,0.05125839,0.0007521657],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842944,0.00603327,0.000003989238,0.006451702,0.001862008,0.0007964169,0.0001350857,0.00001024312,0.0004128932],"genre_scores_gemma":[0.9946898,0.001537783,0.00122506,0.0004148722,0.0005608284,0.0002625787,0.00002262306,0.00005217029,0.001234285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3993309,"threshold_uncertainty_score":0.9996048,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.13108514094083,"score_gpt":0.4633682341905971,"score_spread":0.3322830932497671,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}